World News

EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride

Ogkologos - 4 Αυγούστου, 2022

Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma

Ogkologos - 3 Αυγούστου, 2022

KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,...

Ogkologos - 3 Αυγούστου, 2022

The Benefits of Yoga During Cancer and How to Get Started

Ogkologos - 2 Αυγούστου, 2022

Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with...

Ogkologos - 2 Αυγούστου, 2022

Aided by Community Health Workers, People with Advanced Cancer Need Fewer...

Ogkologos - 1 Αυγούστου, 2022

Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen...

Ogkologos - 29 Ιουλίου, 2022

An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does...

Ogkologos - 29 Ιουλίου, 2022

2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple...

Ogkologos - 28 Ιουλίου, 2022

New Cancer Model Shows Promise in Predicting If Treatment Will Shrink...

Ogkologos - 28 Ιουλίου, 2022

1...182183184...432 Σελίδα 183 από 432

MOST POPULAR

Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic...

27 Ιανουαρίου, 2025

Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA...

15 Απριλίου, 2024

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...

10 Σεπτεμβρίου, 2025

At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement...

27 Φεβρουαρίου, 2024

Φόρτωση περισσοτέρων

EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride

Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma

KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,...

The Benefits of Yoga During Cancer and How to Get Started

Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with...

Aided by Community Health Workers, People with Advanced Cancer Need Fewer...

Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen...

An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does...

2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple...

New Cancer Model Shows Promise in Predicting If Treatment Will Shrink...

MOST POPULAR

Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic...

Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA...

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...

At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement...

HOT NEWS

News digest – Genetic links to male breast cancer, bowel cancer...

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and...

Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her...

Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ